BASF to Build New World-Scale Plant for Specialty Amines in Ludwigshafen
![](/46/pdcnewsitem/02/89/38/sNDkXmkqPzpdtau.png)
BASF is building a new world-scale plant for the production of specialty amines in Ludwigshafen. Start-up of the facility with a total annual capacity of about 12,000 metric tons is scheduled for 2015. The product range of this flexible multi-product plant comprises 15 amines for different applications. The major applications are in the construction, automotive, crop protection and pharmaceutical industries. With this new facility, BASF is expanding its global production network of amines with plants in Ludwigshafen and Schwarzheide in Germany; Antwerp, Belgium; Geismar, Louisiana; and Nanjing, China.
“With the new plant we are responding to our customers’ demand for specialty amines, particularly in Europe,” said Sanjeev Gandhi, President, BASF Intermediates division. “We have decades of experience in developing and manufacturing amines, and with the new plant we are reinforcing our global leadership position in these versatile intermediates.”
“This facility enables us to react flexibly to changes in the demand of individual products. We will also use it to produce commercial quantities of new products from our innovation pipeline,” said Dr Christoph Wegner, head of the regional business unit Amines Europe within BASF’s Intermediates division. “Being integrated into the BASF Verbund at the Ludwigshafen site allows us to scale up products from R&D to pilot scale and to commercial production in this new multi-product plant for our customers.”
BASF had announced in March that it is building another new multi-product plant for the production of specialty amines at the BASF Verbund site in Nanjing, China. The main products of this plant, which is due to start-up operations in 2015, will be dimethylaminopropylamine (DMAPA) and polyetheramine (PEA).
With about 200 different amines, BASF has the world’s most diverse portfolio of this type of chemical intermediates. Along with alkyl-, alkanol-, alkoxyalkylamines, the company offers heterocyclic and aromatic as well as specialty amines. The range is completed by an expanding portfolio of chiral amines of high optical and chemical purity. The versatile products are used mainly to manufacture process chemicals, pharmaceuticals and crop protection products, as well as cosmetic products and detergents. They also serve to produce coatings, special plastics, composites and special fibers.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance